MEK inhibition could lead to increased LGR5 levels, Wnt activity and stemness- and cancer relapse-related gene expression in CRC PDOs, revealing a side effect of MEK inhibition via inducing stem cell plasticity [83]. The gene discussed is MAP2K7; the disease is colorectal carcinoma.